Parkinson's biotech Civitas Therapeutics files for a $86 million IPO
Civitas Therapeutics, a late-stage biotech developing a therapy for symptoms of Parkinson's disease, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
The Chelsea, MA-based company, which was founded in 2009, plans to list on the NASDAQ under the symbol CVTS. Civitas Therapeutics initially filed confidentially on May 12, 2014. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Parkinson's biotech Civitas Therapeutics files for a $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.